SAN FRANCISCO—It was just about a year ago when GlaxoSmithKline sealed its deal for Tesaro, bringing on already-marketed PARP inhibitor Zejula. But don’t expect the company to spring for more commercial-stage oncology products anytime soon.
While “we are not excluding the opportunity” for products on the market, it “has to be a good fit for the situation”—and GSK is being particular about the situation it’s currently in, said Axel Hoos, the company’s SVP of Oncology R&D.